{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:07:23Z","timestamp":1778976443649,"version":"3.51.4"},"reference-count":27,"publisher":"Informa Healthcare","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1185\/030079905x38196","type":"journal-article","created":{"date-parts":[[2005,6,28]],"date-time":"2005-06-28T17:31:46Z","timestamp":1119979906000},"page":"517-526","source":"Crossref","is-referenced-by-count":60,"title":["Efficacy and tolerability of lumiracoxib 100\u2009mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib"],"prefix":"10.1185","volume":"21","author":[{"given":"Reiner","family":"Lehmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Brzosko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Kopsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Nischik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kreiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Thurston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Litschig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor S.","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3197","published-online":{"date-parts":[[2005,4,14]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.suppl_1.3"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.suppl_2.3"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V"},{"key":"CIT0005","first-page":"1905","volume":"43","author":"American College of Rheumatology","year":"2000","journal-title":"American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00372-X"},{"issue":"25","key":"CIT0007","first-page":"S9","volume":"19","author":"Dougados M","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"25","key":"CIT0008","first-page":"S3","volume":"19","author":"Moskowitz RW","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199906173402407"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.suppl_1.7"},{"key":"CIT0015","first-page":"1520","volume":"343","author":"Bombardier C","year":"2000","journal-title":"VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1080\/03009740310004766"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0645rev"},{"key":"CIT0022","first-page":"467","volume":"43","author":"Scott G","year":"2004","journal-title":"Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet"},{"issue":"25","key":"CIT0025","first-page":"S59","volume":"19","author":"Day RO","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"CIT0026","first-page":"1804","volume":"31","author":"Hawkey CJ","year":"2004","journal-title":"Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis. J Rheumatol"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.01956.x"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02026.x"},{"key":"CIT0029","first-page":"665","volume":"364","author":"Schnitzer TJ","year":"2004","journal-title":"TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet"},{"key":"CIT0033","first-page":"1039","volume":"29","author":"Altman R","year":"1986","journal-title":"Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum"},{"key":"CIT0034","first-page":"1833","volume":"15","author":"Bellamy N","year":"1988","journal-title":"Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol"},{"key":"CIT0035","first-page":"395","volume":"8","author":"Dougados M","year":"2000","journal-title":"Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage"},{"key":"CIT0036","first-page":"1648","volume":"30","author":"Pham T","year":"2003","journal-title":"OMERACT-OARSI. Outcome variables for osteoarthritis clinical trials: The OMERACT-OARSI set of responder criteria. J Rheumatol"},{"key":"CIT0037","first-page":"29","volume":"64","author":"Tubach F","year":"2005","journal-title":"Evaluation of clinically relevant changes in patient- reported outcomes in knee and hip osteoarthritis: the Minimal Clinically Important Improvement. Ann Rheum Dis"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1080\/030097401750065265"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1053\/joca.2001.0510"},{"key":"CIT0041","first-page":"675","volume":"364","author":"Farkouh ME","year":"2004","journal-title":"TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARG ET), cardiovascular outcomes: randomised controlled trial. Lancet"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp048288"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/030079905X38196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T08:43:58Z","timestamp":1481618638000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1185\/030079905X38196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,4,3]]},"published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1185\/030079905X38196"],"URL":"https:\/\/doi.org\/10.1185\/030079905x38196","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}